糖尿病血液透析患者中持续葡萄糖监测的准确性
研究纳入31例维持性血液透析的糖尿病患者,比较Dexcom G6持续葡萄糖监测(CGM)与血糖测量的准确性和一致性。CGM与血糖的相关系数为0.84和0.79,平均绝对相对差约20%,共识误差网格显示几乎所有CGM值位于临床可接受区域。作者认为需进一步研究确定CGM能否改善血液透析患者结局。
要点
- CGM与血糖Pearson相关系数0.84,Spearman相关系数0.79。
- CGM与血糖平均差约+15 mg/dL,平均绝对相对差约20%。
- 共识误差网格显示几乎所有CGM值位于临床可接受区域A和B。
核心结论
- 在糖尿病血液透析患者中,平均绝对相对差高于传统最佳分析性能阈值,但误差网格显示几乎所有CGM值位于临床可接受区域。
- 需进一步研究确定CGM能否改善血液透析患者结局。
研究设计与样本
- 研究纳入2020年10月至2021年5月住院的31例维持性血液透析糖尿病患者,进行规范化葡萄糖测量,比较Dexcom G6 CGM与血糖(餐前、夜间及透析期间每30分钟测量一次)。
主要发现
- 平均CGM与血糖的Pearson相关系数为0.84,Spearman相关系数为0.79。
- Bland-Altman分析显示CGM与血糖的平均差约为+15 mg/dL。
- 采用%20/20标准的总体、透析期间和非透析期间一致率分别为48.7%、47.2%和50.2%。
- 所有时间段平均绝对相对差(MARD)约为20%;总体中位绝对相对差为19.4%,非透析期间为18.2%,透析期间为22.0%。
- 共识误差网格显示几乎所有CGM值位于临床可接受区域A(无伤害)和B(不太可能造成显著伤害)。
关键数值与推荐
- 平均CGM与血糖的Pearson相关系数为0.84,Spearman相关系数为0.79。
- CGM与血糖的平均差约为+15 mg/dL。
- 采用%20/20标准的一致率:总体48.7%,透析期间47.2%,非透析期间50.2%。
- 总体中位绝对相对差为19.4%,非透析期间为18.2%,透析期间为22.0%。
- 几乎所有CGM值位于共识误差网格的临床可接受区域A和B。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究确定CGM能否改善血液透析患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypoglycemia and hyperglycemia and increased time in target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients. RESEARCH DESIGN AND METHODS: Among 31 maintenance hemodialysis patients with diabetes hospitalized from October 2020 to May 2021, we conducted protocolized glucose measurements using Dexcom G6 CGM versus blood glucose, with the latter measured before each meal and at night, plus every 30-min during hemodialysis. We examined CGM-blood glucose correlations and agreement between CGM versus blood glucose using Bland-Altman plots, percentage of agreement, mean and median absolute relative differences (ARDs), and consensus error grids. RESULTS: Pearson and Spearman correlations for averaged CGM versus blood glucose levels were 0.84 and 0.79, respectively; Bland-Altman showed the mean difference between CGM and blood glucose was ∼+15 mg/dL. Agreement rates using %20/20 criteria were 48.7%, 47.2%, and 50.2% during the overall, hemodialysis, and nonhemodialysis periods, respectively. Mean ARD (MARD) was ∼20% across all time periods; median ARD was 19.4% during the overall period and was slightly lower during nonhemodialysis (18.2%) versus hemodialysis periods (22.0%). Consensus error grids showed nearly all CGM values were in clinically acceptable zones A (no harm) and B (unlikely to cause significant harm). CONCLUSIONS: In hemodialysis patients with diabetes, although MARD values were higher than traditional optimal analytic performance thresholds, error grids showed nearly all CGM values were in clinically acceptable zones. Further studies are needed to determine whether CGM improves outcomes in hemodialysis patients.
引用
- Narasaki Y, Kalantar-Zadeh K, Daza AC, et al. Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes. Diabetes Care. 2024. PMID: 39213372. doi:10.2337/dc24-0635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。